Literature DB >> 7797836

Hepatotoxicity and accelerated fibrosis following 3,4-methylenedioxymetamphetamine ("ecstasy") usage.

S I Khakoo1, C J Coles, J S Armstrong, R E Barry.   

Abstract

3,4-Methylenedioxymetamphetamine ("ecstasy") has previously been reported to cause an acute hepatitis that may progress to liver failure. We present the first recorded case of ecstasy-induced accelerated hepatic fibrosis.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7797836     DOI： 10.1097/00004836-199504000-00017

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN： 0192-0790            Impact factor:   3.062


  3 in total

Review 1.  The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.

Authors:  H Kalant
Journal:  CMAJ       Date:  2001-10-02       Impact factor: 8.262

Review 2.  3,4-methylenedioxymethamphetamine (MDMA): a review.

Authors:  G O'Leary; J Nargiso; R D Weiss
Journal:  Curr Psychiatry Rep       Date:  2001-12       Impact factor: 8.081

3.  Pentoxifylline Protects the Rat Liver Against Fibrosis and Apoptosis Induced by Acute Administration of 3,4-Methylenedioxymethamphetamine (MDMA or Ecstasy).

Authors:  Shabnam Movassaghi; Zahra Nadia Sharifi; Farzaneh Mohammadzadeh; Mansooreh Soleimani
Journal:  Iran J Basic Med Sci       Date:  2013-08       Impact factor: 2.699
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.